Advertisement
News
Advertisement

Cancer Spread’s ‘Family Tree’

Wed, 04/23/2014 - 12:34pm
(Source: HMS)The process of metastasis— a tumor’s ability to spread to other parts of the body— is still poorly understood. It has not been easy to determine whether metastasis began early or late in the development of the primary tumor, or whether individual metastatic sites were seeded directly from the original tumor or from an intermediate site. Now a research team has developed a simple test that can reveal the evolutionary relationships among various tumor sites within a patient, information that may someday help with treatment planning.
 
“If we could build a ‘family tree’ of all cancer nodules in a patient, we could determine how different tumors are related to each other and reconstruct how the cancer evolved,” said Kamila Naxerova, Harvard Medical School research fellow in radiation oncology in the Steele Laboratory for Tumor Biology at Massachusetts General Hospital. She is corresponding author of the report, published in PNAS Early Edition. “Usually that would require extensive genetic analysis with complex sequencing methods, but our methodology achieves that goal quickly and with minimal experimental effort.”
 
Cancer researchers are just beginning to investigate the extent and significance of genetic differences among tumor cells, either among cells within a discrete tumor or between a primary tumor and metastases in other parts of the body. The authors note that there are two different models of metastasis. In one model, an advanced primary tumor disseminates metastatic cells late in its development, which would predict little genetic difference between primary and metastatic cells. In the other model, metastasis occurs early in tumor development, which would predict significant genetic differences in metastatic cells that have evolved separately from those in the primary tumor. Some studies have suggested that the two models apply to different types of cancer, but patient data so far has been limited.
 
Answering important clinical questions, such as whether genetic diversity is a risk factor for aggressive tumor development and how it relates to treatment resistance, requires analyzing samples from many patients with different types of cancer. Sequencing the whole genome or just the protein-coding portion of the genome (the exome) requires specialized equipment and advanced data analysis, making the process relatively expensive.
 
The approach developed by the Mass General team focuses on small areas of the human genome called polyguanine (poly-G) repeats that are particularly susceptible to mutation, with genetic “mistakes” occurring frequently during cell division. While these mutations do not directly relate to the development or progression of a tumor, they can reveal its lineage—how individual tumor cells are related to each other.
 
Poly-G repeat analysis was initially developed to study lineage relationships between single cells in mice, but in the current paper, the authors adapted it to study human cancer for the first time. Analyzing the poly-G profiles of primary and metastatic colon cancer samples from 22 patients revealed that the way the primary and metastatic tumors related to each other was different for each patient.
 
In some individuals there were significant genetic differences between tumor sites, suggesting early metastatic spread; in others, there was little difference between a primary tumor and its metastases. The investigators also identified instances in which the genetic profiles of metastases were similar to those of only some cells in the primary tumor, suggesting that those cells were the source of the metastases, and other cases in which the genetic profiles of metastases from the same primary tumor differed depending on their location.
 
“We found that there are several paths that can lead to metastatic disease,” said Naxerova. “We are now applying this methodology to address specific clinically relevant questions about the biology of metastasis in larger numbers of patients. The method is fast and inexpensive and should be applicable to other types of tumors than colon cancer.”
 
Co-author Elena Brachtel, HMS assistant professor of pathology at Mass General, noted that archival tissues from the files of the department were used for this study. “After diagnostic studies on tissue removed during a patient’s operation are completed, the formalin-fixed paraffin tissue blocks are stored for several years. Increasingly, new molecular tests can be performed on tissue that was removed from a patient several years earlier, at a time when these tests were not yet available.”
 
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading